Elevated plasma F2-isoprostanes in patients on long-term hemodialysis  by Handelman, Garry J. et al.
Kidney International, Vol. 59 (2001), pp. 1960–1966
Elevated plasma F2-isoprostanes in patients on
long-term hemodialysis
GARRY J. HANDELMAN,1 MARY F. WALTER, ROHINI ADHIKARLA, JONATHAN GROSS,
GERARD E. DALLAL, NATHAN W. LEVIN, and JEFFREY B. BLUMBERG
Antioxidants Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University,
Boston, Massachusetts, and Renal Research Institute, New York, New York, USA
interventions to decrease oxidative stress and associated in-Elevated plasma F2-isoprostanes in patients on long-term hemo-
flammation.dialysis
Background. End-stage renal disease (ESRD) patients on
long-term hemodialysis (HD) may be under increased oxi-
dative stress, caused by either HD or renal failure. Plasma
Oxidative stress may be a significant contributor to theF2-isoprostanes have been established as an important indica-
accelerated pathology associated with end-stage renaltor of in vivo oxidative stress.
Methods. Plasma esterified F2-isoprostanes were measured in disease (ESRD) [1]. Oxidative stress may contribute to
25 HD patients and 23 controls with normal renal function, em- heart disease and other circulatory disturbances [2], com-
ploying gas chromatography-mass spectrometry with negative plicate the clinical picture of diabetes [3], and increasechemical ionization (GC-MS-NCI). C-reactive protein (CRP)
the susceptibility to HIV infection [4]. The potentialwas determined concurrently in patients and controls by en-
synergy between inflammation and oxidative stress is ofzyme-linked immunosorbent assay (ELISA). a-Tocopherol,
retinol, albumin and creatinine were also determined. particular concern since inflammation is a major compo-
Results. The average total esterified F2-isoprostanes in the nent of long-term morbidity in dialysis patients [5–7].
ESRD patients was 1.62 6 0.73 vs. 0.27 6 0.10 ng/mL in controls
Decreased levels of specific antioxidant defenses, such(P , 0.001), with no overlap between patients and controls.
as vitamin E, vitamin C, glutathione (GSH), Se-glutathi-Plasma F2-isoprostanes in diabetic ESRD patients were similar
to F2-isoprostanes in patients with other causes for renal failure. one-peroxidase (Se-GSH-Px), and superoxide dismutase
In a subset of 10 of these ESRD patients evaluated eight months (SOD), could lead to increased oxidative stress in ESRD
after the initial measurement, plasma-esterified F2-isopros- patients. Plasma vitamin C was found to be very low intanes were not altered by an individual dialysis session. Aver-
studies conducted in the period from 1980 to 1995 [8]age plasma CRP values were also higher in HD patients (P ,
because of the loss of vitamin C during hemodialysis (HD)0.02), but some patients had CRP values that were similar to
controls. In the HD patients, total plasma F2-isoprostanes and [9]. In current protocols, regular use of dietary vitamin
plasma CRP were correlated (r 5 0.48, P 5 0.015). Plasma C supplements has partly remedied the vitamin C defi-
a-tocopherol did not differ between patients and controls, but
ciency in HD patients [10, 11]. Low levels of plasma Seplasma retinol was higher in patients (3.15 6 1.71 mmol/L)
have been detected in several studies of dialysis patientsthan in controls (1.97 6 0.51 mmol/L, P , 0.05).
Conclusions. These results are consistent with the hypothe- [12–14]. Other antioxidant defenses show a great deal
sis that oxidative stress in ESRD patients contributes to in- of variation but are often in the normal range.
creased values of esterified plasma F2-isoprostanes, with concur- The hypothesis that increased oxidative stress is a fac-rent increases in plasma CRP levels in some patients. Impaired
tor in dialysis pathology has led to study of vitaminclearance of esterified F2-isoprostanes may contribute to the
elevated levels in renal failure. Plasma esterified F2-isopros- E-coated dialyzers [15] and to an evaluation of antioxi-
tanes may be a useful indicator to evaluate effectiveness of dant supplements for ESRD patients [16], but results
from these investigations are not yet conclusive.
Indicators of oxidative stress have often been evalu-1 Current address is Department of Health and Clinical Science, Uni-
versity of Massachusetts, Lowell, MA, USA. ated in ESRD patients. Plasma malondialehyde (MDA)
is frequently elevated, but the results can be contradic-Key words: end-stage renal disease, C-reactive protein, oxidative stress,
inflammation. tory; for example, one study found that an individual
dialysis session lowered plasma MDA by an average of
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Fig. 1. Pathway for enzymatic synthesis of prostaglandin F2a and for free-radical initiated synthesis of F2-isoprostanes.
lyzer clearance of MDA. Oxidative stress can also be smokers [24] and in subjects with type 2 diabetes [25].
Because plasma clearance of free isoprostanes might beevaluated from low-density lipoprotein (LDL) oxidation
ex vivo, but LDL isolated from ESRD patients may affected by renal mechanisms and by HD, we optimized
our methodology [26] for the measurement of esterifiedeither be more vulnerable to ex vivo oxidation than con-
trol LDL [19] or be similar to control LDL [20]. For most plasma F2-isoprostanes. We sought to measure esterified
plasma isoprostanes in both ESRD patients and controlsindices of oxidative stress, there is substantial overlap
between ESRD patients and controls, although average of similar age.
values may differ.
The F2-isoprostanes are derived from oxidative modi-
METHODSfication of arachidonic acid [21, 22]. When arachidonic
Patients and controlsacid is attacked by an initiating radical species, the ara-
chidonic acid double bond structure undergoes a com- Patients on long-term HD were recruited from a Renal
Research Institute dialysis clinic in New York (NY, USA).plex set of radical rearrangements, which terminates in
metabolites with three OH groups (Fig. 1). These metab- All patients were dialyzed with polysulfone dialyzers.
The etiology for renal failure was diabetes in 13 patientsolites, called F2-isoprostanes, are less reactive than other
products of lipid peroxidation and are useful markers and hypertension or other causes in 12 patients (Table 1).
Normal controls were recruited from middle-aged andfor the assessment of vivo oxidative stress. F2-isopros-
tanes are elevated in experimental animals following older adults in Boston (MA, USA) and were of similar
age to the ESRD patients. Control subjects were screenedtreatment with CCl4, which is a very strong pro-oxidant
[23]. Plasma F2-isoprostanes are elevated in cigarette using fasting blood samples and were excluded for ele-
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Table 1. Characteristics of hemodialysis patients and mined by enzyme-linked immunosorbent assay (ELISA)
control subjects
[28], with a lower detection limit of 0.1 mg CRP/L. Plasma
Patients (N525) Controls (N523) albumin and creatinine were determined by standard clini-
Age mean6SD 64615 6065.6 cal methods at Spectra-East Labs (Rutherford, NJ, USA).
Sex
Female 19 18 Statistical analyses
Male 6 5
Race Black511 Caucasian522 F2-isoprostanes, CRP, and other variables were com-
Hispanic59 Asian51 pared between dialysis patients and controls by usingCaucasian55
the Student t-test for independent samples. The PearsonTime on dialysis years 2.361.9
Cause of renal failure correlation coefficient was used to measure the associa-
Diabetes 13 tion between plasma F2-isoprostanes and plasma CRP,Hypertension 4
after logarithmic transformation of each variable. Analy-Other 8
ses were carried out with Systat for Windows, version
7.0.1 (SPSS Inc., Chicago, IL, USA). Data are reported
as mean 6 SD.
vated plasma cholesterol (.250 mg/dL), plasma triglyc-
erides (.200 mg/dL), and blood glucose (.150 mg/dL).
RESULTSNormal renal function in controls was established by a
lack of urinary protein or casts and by plasma creatinine Total plasma esterified F2-isoprostanes in ESRD
,1.5 mg/dL. The collection of blood samples from pa- patients and control subjects
tients and controls was approved by the respective insti- The average value for total esterified plasma F2-iso-
tutional review boards of Beth Israel Medical Center prostanes was much higher for ESRD patients (1.62 6
(New York, NY, USA) and the Tufts/New England Med- 0.73 ng/mL) than for control subjects (0.27 6 0.10 ng/mL,
ical Center (Boston, MA, USA). Informed consent was P , 0.001). There was no overlap between the patient
obtained prior to the collection of blood samples. The and control groups; the lowest isoprostane value re-
description of both patient and control groups is reported ported for ESRD patients (0.64 ng/mL) was larger than
in Table 1. the highest isoprostane value in the control subjects
(0.47 ng/mL; Fig. 2).Sampling procedures
Diabetes was responsible for ESRD in 13 patients, andBlood samples for isoprostanes were drawn with ethyl-
the level of esterified F2-isoprostanes in diabetic patientsenediaminetetraacetic acid (EDTA) anticoagulant and
was 1.53 6 0.54 ng/mL. In 12 other patients, ESRD wascentrifuged within 10 minutes of collection. Plasma was
caused by hypertension and other causes; in these pa-snap frozen in liquid nitrogen in plastic vials with tight-
tients, esterified F2-isoprostanes were 1.71 6 0.84 ng/mLfitting caps and stored at 2808C until measurement of
(P , 0.001, for these patients compared with controls).isoprostane content. Samples from ESRD patients were
typically collected during the course of the dialysis session. Plasma C-reactive protein
Other plasma aliquots were obtained for determina-
The mean value for plasma CRP was also elevated intion of a-tocopherol, retinol, C-reactive protein (CRP),
the dialysis patients (19.7 6 28.8 mg/L) compared withalbumin, and creatinine for evaluation of clinical status
controls (2.1 6 2.9 mg/L) (P , 0.02); however, someof ESRD patients.
control subjects had CRP values comparable to dialysis
patients (Fig. 3).Laboratory procedures
Plasma esterified F2-isoprostanes were measured by
Plasma a-tocopherol and retinol in both groupsgas chromatography-mass spectrometry with negative
There were no significant differences in plasma a-toco-chemical ionization (GC-MS-NCI), as described by Wal-
pherol levels between patients and controls (Table 2).ter et al [26]. Briefly, esterified plasma lipids were isolated
However, patients had a higher level of plasma retinolwith Folch extraction, followed by gentle alkaline hydro-
(P , 0.05; Table 2), which is consistent with previouslysis to release free isoprostanes. The isoprostanes were
observations of patients on HD [11, 29, 30].converted to pentafluorobenzyl esters and purified by
high-performance liquid chromatography (HPLC) on an
Associations between isoprostanes and other clinicalamino bonded-phase column. The purified isoprostanes
parameters in hemodialysis patientswere silylated and analyzed on a Trio-1000 mass spectrom-
The levels of plasma F2-isoprostanes and CRP wereeter, interfaced with an HP 5890-II gas chromatograph.
compared in the patients on HD; the data are plottedPlasma a-tocopherol and retinol were measured by
HPLC with ultraviolet detection [27]. CRP was deter- on logarithmic axes in Figure 4. High levels of F2-iso-
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Fig. 3. Levels of C-reactive protein (CRP) in ESRD patients and con-Fig. 2. Levels of esterified F2-isoprostanes in end-stage renal disease
trols. The difference is significant (P , 0.02).(ESRD) patients and controls. The difference is significant (P , 0.001).
Table 2. Plasma a-tocopherol and retinol valuesprostanes in the dialysis patients were correlated with
Patients Controlshigh plasma CRP (r 5 0.48, P 5 0.015).
(N525) (N523)Additional plasma CRP measurements were available
a-Tocopherol lmol/L 25.968.7 29.468.1for several months prior and following the dialysis ses-
Retinol lmol/L 3.1361.68a 1.9760.51sion where plasma F2-isoprostane values were deter-
a P , 0.05mined. Although some patients showed a longitudinal
trend toward increasing CRP values and others toward
decreasing CRP, this was not associated with the level
of plasma F2-isoprostanes. Plasma creatinine was also on 10 patients randomly selected from our initial group
evaluated as an indicator of dialysis adequacy, but there of 25 patients. The average plasma F2-isoprostanes for
was no association with levels of plasma F2-isoprostanes this set of 10 patients before dialysis was 1.52 ng/mL
(r 5 0.146, P 5 0.67). (60.43 ng/mL), and following the dialysis session the
Plasma albumin values failed to correlate with F2-iso- value was 1.53 ng/mL (60.42 ng/mL; Fig. 5).
prostane measurements. However, there was a trend to-
ward an inverse correlation between plasma albumin
DISCUSSIONand CRP (r 5 20.35, P 5 0.06), as has been reported
in previous investigations [31]. Our finding that plasma isoprostanes are elevated in
patients on HD is consistent with the hypothesis that
Effect of a single hemodialysis session on plasma these patients are under increased oxidative stress. Di-
esterified F2-isoprostane levels verse mechanisms might account for increased oxidative
For a subset of patients evaluated in the initial part of stress, including antioxidant deficiency, neutrophil acti-
this study, esterified plasma isoprostanes were measured vation during dialysis, and chronic inflammation.
before the start of dialysis and after the termination of Pathology associated with oxidative stress has been
the dialysis session. This measurement was carried out reported in experimental animals when plasma antioxi-
dants decrease to 25% or less of normal values [32]. Ineight months after the initial isoprostane determination
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Fig. 4. Plasma CRP and F2-isoprostanes in hemodialysis patients, plot-
ted on logarithmic axes for each variable.
most studies of ESRD patients, however, plasma antioxi-
dants are within 75% of normal values [10, 18, 33], and
the increased levels of isoprostanes in these patients are
unlikely to be caused by severe antioxidant deficiency.
Degranulation of neutrophils passing through the dial-
ysis cartridge has been reported [34], and neutrophil
activation by HD must be considered as a potential con- Fig. 5. Effects of a single dialysis session on plasma esterified F2-iso-
prostanes in 10 ESRD patients. F2-isoprostanes in plasma from eachtributor to oxidative stress. Although the individual dial-
patient were measured before and after the HD session.ysis sessions led to no consistent increase or decrease in
esterified F2-isoprostanes (Fig. 5), the increase in plasma
isoprostanes seen in ESRD patients may reflect a chronic
oxidant stress imposed by frequent dialysis or by circum- to increase in renal failure. On the other hand, since free
stances extraneous to the dialysis procedure. We have isoprostanes are charged compounds of low molecular
undertaken studies to determine levels of F2-isopros- weight (321 D), free isoprostanes might be cleared during
tanes during the course of renal failure that would evalu- HD. Since esterified isoprostanes would be metabolized
ate separately the contributions of renal failure and the primarily by hepatic mechanisms, the esterified fraction
dialysis process. is a more suitable index of oxidative stress in ESRD
Patients on dialysis frequently show markers of chronic patients than the free isoprostane fraction. In future stud-
inflammation [5, 6, 35–37], and oxidative stress is a sig- ies, we will adapt our protocol to measure the free iso-
nificant component of the inflammatory process [38]. prostane fraction as well as the esterified fraction in
Reactive oxygen species released by activated white cells patients with ESRD.
[39] may account for a portion of the oxidative stress Previous investigations have reported that plasma iso-
found in chronic inflammation. prostanes were elevated approximately twofold in type
The elevated levels of F2-isoprostanes seen in ESRD II diabetic patients, as compared with controls [25]. This
patients might also derive from impaired clearance might have contributed to a portion of the elevated
mechanisms for esterified isoprostanes, which may be F2-isoprostanes levels seen in the diabetic patients
altered during renal failure. Since the clearance of esteri- (1.53 6 0.54 ng/mL). However, the ESRD patients in
fied F2-isoprostanes is not well understood at present, which renal failure was caused by hypertension or other
other mechanisms besides oxidative stress may contrib- causes also had elevated levels of esterified F2-isopros-
ute to the elevated levels of F2-isoprostanes. tanes (1.71 6 0.84 ng/mL).
We chose to measure plasma esterified F2-isopros- Our control subjects were mostly Caucasian, whereas
tanes because isoprostanes covalently bound to plasma the dialysis patients were preponderantly Hispanic and
lipids would not be subject to either renal clearance or African American. However, a subgroup analysis of the
to removal during HD. Free (nonesterified) F2-isopros- dialysis patients indicated that the five Caucasian sub-
tanes appear in the urine of subjects with normal renal jects had the highest plasma isoprostanes among the
25 dialysis patients (1.74 6 0.63 ng/mL) compared withfunction [40, 41], and plasma levels might be expected
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